Retrospective cohort study finds higher tofacitinib effectiveness in elderly ulcerative colitis patients than younger peers, highlighting therapeutic viability across older demographics.
INTRODUCTION: There is paucity of data on the effectiveness and safety of tofacitinib among elderly patients with ulcerative colitis (UC). METHODS: Through a retrospective cohort study among the US National Veterans Affairs Healthcare System, we evaluated effectiveness among the elderly (≥65) and young (<65) patients with UC initiated on tofacitinib. RESULTS: Among 158 patients (53 elderly, 105 young), effectiveness at 12 months was 50.94% in the elderly and 33.33% in the young ( P = 0.032). DISCUSSION: In a nationwide cohort of patients with UC initiating tofacitinib, effectiveness was seen in half of the elderly patients.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: